Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3998104 | 0.86 | MEN1 (0.41) | ALDH1A1TSHRMEN1CYP3A4ALOX15 | |
| SCHEMBL14413091 | 0.82 | LMNA (0.40) | ALDH1A1TSHRMEN1CYP3A4ALOX15 | |
| SCHEMBL18881747 | 0.82 | MEN1 (0.33) | ALDH1A1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL8621930 | 0.81 | TDP1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL746944 | 0.79 | TSHR (0.46) | TSHR | |
| SCHEMBL29172874 | 0.79 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13061540 | 0.79 | LMNA (0.54) | ALDH1A1MEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL6178207 | 0.78 | ACACB (0.35) | — | |
| SCHEMBL14220647 | 0.77 | TSHR (0.33) | TSHR | |
| SCHEMBL2113825 | 0.77 | ALDH1A1 (0.44) | ALDH1A1TSHRMEN1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9890178-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-13 | — | — | US | disclosed |
| CN-107428991-A | Tri trimellitate ester plasticiser and the vinyl chloride resin composition containing it | 株式会社ADEKA | 2017-12-01 | — | — | CN | disclosed |
| US-9567550-B2 | Fragrance composition | KAO CORPORATION (JP) | 2017-02-14 | — | — | US | disclosed |
| US-9468884-B2 | Process for removing acidic compounds from a gaseous effluent with an absorbent solution based on dihydroxyalkylamines bearing severe steric hindrance of the nitrogen atom | IFP Energies Nouvelles (FR) | 2016-10-18 | — | — | US | disclosed |
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9321767-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-26 | — | — | US | disclosed |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | ALIOS BIOPHARMA, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2015-03-12 | — | — | US | disclosed |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-03-12 | — | — | US | disclosed |
| US-8927720-B2 | Azabenzimidazoles as respiratory syncytial virus antiviral agents | JANSSEN R&D IRELAND (IE) | 2015-01-06 | — | — | US | disclosed |
| US-8299246-B2 | N-cyclopropyl-3-fluoro-5-[3-[[1-[2-[2- [(2-hydroxethyl)amino] ethoxy]phenyl] cyclopropyl] amino]-2-oxo-1 (2H)-pyrazinyl]-4-methyl-benzamide, or pharmaceutically acceptable salts thereof and their uses | ASTRAZENECA AB (SE) | 2012-10-30 | — | — | US | disclosed |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | ASTRAZENECA AB (SE) | 2012-08-23 | — | — | US | disclosed |
| US-8163905-B2 | Compounds and their uses 708 | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-7186782-B2 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2007-03-06 | — | — | US | disclosed |
| US-20060041079-A1 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6881797-B2 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2005-04-19 | — | — | US | disclosed |
| US-20040082727-A1 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (CN) | 2004-04-29 | — | — | US | disclosed |
| US-4859759-A | Siloxane containing benzotriazolyl/tetraalkylpiperidyl substituent | KIMBERLY-CLARK CORPORATION (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237096-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | AZI2, ZC3HAV1, ZC3HAV1L | ALDH1A1 1885/4885TSHR 4377/4885MEN1 1688/4885 |
| US-20100240659-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY | HSD11B1, HSD3B1, SRD5A1 | ALDH1A1 208/4885TSHR 2763/4885MEN1 1843/4885 |
| US-20150073012-A1 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | ZC3HAV1, AZI2, ZC3HAV1L | ALDH1A1 2104/4885TSHR 4359/4885MEN1 1913/4885 |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | ALDH1A1 340/4885TSHR 403/4885MEN1 1541/4885 |
| US-20160045528-A1 | COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS | MAVS, EIF2AK2, SARS1 | ALDH1A1 2576/4885TSHR 3851/4885MEN1 4014/4885 |
| US-20120214822-A1 | N-CYCLOPROPYL-3-FLUORO-5-[3-[[1-[2-[2- [(2-HYDROXETHYL)AMINO] ETHOXY]PHENYL] CYCLOPROPYL] AMINO]-2-OXO- 1 (2H)-PYRAZINYL]-4-METHYL-BENZAMIDE, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND THEIR USES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-0, CYP3A5 | ALDH1A1 243/4885TSHR 513/4885MEN1 3120/4885 |
| US-20150073136-A1 | PYRAZINONE DERIVATIVES | CYP3A7, CYP3A4, CYP2D6 | ALDH1A1 466/4885TSHR 157/4885MEN1 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.